Zotuximab is developed and produced by which company?

Zolbetuximab (zolbetuximab-clzb)-VYLOY is an innovative targeted monoclonal antibody drug developed and produced by Astellas Pharma Inc., a well-known Japanese pharmaceutical company. The drug specifically targets Claudin 18.2 (CLDN18.2), a tight junction protein highly expressed in gastric cancer and gastroesophageal junction adenocarcinoma. As an antibody drug with a highly specific target, the development of zotuximab marks the implementation of CLDN18.2 targeted therapy strategy in clinical treatment, and also provides a new treatment path for gastric cancer and other digestive system tumors. Zotuximab was originally discovered and developed by Ganymed Pharmaceuticals, which was acquired by Astellas in 2016, which accelerated the late-stage development and global clinical advancement of this drug.

Astellas has conducted a number of key clinical studies on zotuximab globally, and has made important progress in the field of gastric cancer in particular. In clinical trials, VYLOY has shown significant survival benefit for patients with CLDN18.2-positive, HER2-negative advanced gastric cancer or gastroesophageal junction cancer, especially when combined with standard chemotherapy regimens such as CAPOX, showing better median progression-free survival and overall survival. Therefore, VYLOY has become one of the most high-profile innovative drugs in the field of gastric cancer targeted therapy in recent years. Astellas is also planning to further expand its indications to other solid tumor types expressing CLDN18.2, such as pancreatic cancer.

In the United States,VYLOY has been approved by the FDA for the treatment of patients positive for specific molecular markers, and its launch in other countries and regions is also gradually advancing. In the Chinese market, although VYLOY is still in its infancy, it has attracted great clinical attention due to its clear target, high efficacy and differentiated advantages. Astellas is working closely with Chinese regulatory authorities to advance its localized clinical and registration processes to accelerate its entry into the Chinese market.

Reference materials:https://www.astellas.com/en/news/29401